Dentsply Sirona Names Daniel Scavilla as New CEO as Simon Campion Departs

airdrop_whisperer · 2026-03-26T04:07:54+00:00

Dentsply Sirona Inc. announced leadership changes with Simon Campion stepping down as CEO on July 31, 2025, replaced by Daniel Scavilla. The company reported Q2 net sales of $935 million, and shares rose 2.04%, reflecting positive market sentiment.

airdrop_whisperer

2026-03-26 04:07:54

Abstract generation in progress

Dentsply Sirona Inc. (XRAY) announced a significant leadership transition on Monday, revealing that Simon Campion will step down as President and Chief Executive Officer effective July 31, 2025. The dental solutions company has tapped Daniel Scavilla to assume the CEO role beginning August 1, 2025, marking the beginning of a new chapter for the dental equipment sector leader.

Simon Campion Concludes Tenure at Dentsply Sirona

The departure of Simon Campion comes as the company navigates evolving market conditions in the dental technology and medical devices sector. His exit on July 31 represents a planned transition aimed at bringing fresh leadership to the organization. The company has ensured continuity by announcing Scavilla’s appointment effective immediately following Campion’s departure.

New CEO Brings Extensive Medical Device Background

Daniel Scavilla arrives at Dentsply Sirona with substantial leadership experience in the healthcare and medical device industry. Most recently, Scavilla served as President and Chief Executive Officer of Globus Medical, Inc. (GMED), a prominent player in the spinal implant and medical device market. His track record in leading major healthcare companies positions him to guide Dentsply Sirona through its next growth phase.

Q2 Financial Performance Meets Expectations

Alongside the leadership announcement, Dentsply Sirona disclosed preliminary financial results for the second quarter ended June 30, 2025. The company reported net sales of approximately $935 million, with adjusted earnings per share ranging from $0.50 to $0.52. These figures reflect the company’s continued operational performance during the transition period.

Market Reaction Reflects Confidence

In pre-market trading, XRAY shares are quoted at $16, up 2.04 percent on the Nasdaq. The modest positive movement suggests market participants are viewing the leadership transition and financial results favorably. The appointment of an experienced executive like Daniel Scavilla, combined with solid Q2 preliminary results, appears to have bolstered investor sentiment in the dental equipment company.

Disclaimer: The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.